
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech is a promising stock due to their growing oncology pipeline, including a successful cancer immunotherapy drug, Comirnaty. The company's collaborations with leaders like Pfizer and Merck, along with their potential for accelerated approval and a well-structured financial outlook, make it a positive investment choice. With their diversified approach to multiple diseases, BioNTech shows strong potential for long-term success.
Bears say
BioNTech is facing several risks, including negative data for its various pipeline drugs, slower market uptake, and failure to advance programs in a timely manner. Additionally, clinical and regulatory risks could delay revenue generation and impact the company's financial projections. The recent departure of BioNTech's co-founders to focus on a new mRNA biotech company also raises concerns about the company's commitment to its current oncology focus and partnership with Bristol-Myers Squibb. While the company has potential in its pipeline and partnerships, these risks lead to a negative outlook for BioNTech's stock.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares